Ionis Pharmaceuticals
Tracked across 3 events · 19 articles · First seen Apr 20, 2026 · Last active Jun 30, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Ionis Pharmaceuticals entered into a license agreement with Recordati for zilganersen outside the U.S., retaining U.S. commercial rights and receiving an upfront payment of $30 million, milestone payments, and royalties. This deal strengthens its position in neurology and rare diseases.
Jun 25, 2026 · 6 articles
Regulatory
Impact: Ionis Pharmaceuticals, a mid-sized drugmaker, expressed disinterest in the United States — Medicaid pilot program due to its business model and limited upside, highlighting the challenges in getting smaller companies to participate.
Apr 20, 2026 · 6 articles
Tech
Impact: Ionis Pharmaceuticals discovered diranersen and licensed it to Biogen in 2019, making it a beneficiary of any future success of the drug.
May 14, 2026 · 7 articles
100
Ionis Pharmaceuticals entered license agreement RecordatiIonis, Recordati License...
95
Recordati obtained exclusive rights Ionis PharmaceuticalsIonis, Recordati License...
80
Ionis Pharmaceuticals received upfront payment RecordatiIonis, Recordati License...
60
Ionis Pharmaceuticals expressed disinterestTrump's Medicaid Drug Price Pilot
60
United States — Food and Drug Administration granted designations Ionis PharmaceuticalsIonis, Recordati License...
40
European Union — European Medicines Agency granted designation Ionis PharmaceuticalsIonis, Recordati License...
ERGEN INTELLIGENCE
Track Ionis Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard